Nab-paclitaxel
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-NAB-PACLITAXEL |
|---|---|
| Tipo | Fármaco |
| Aliaces | ABI-007AbraxanoNab-paclitaxel (paclitoxel encuadrado con alcohol)Paclitaxel encuadrado en la albuminaНаб-паклітаксел |
| Situación | reviewed 2026-04-26 | pending_clinical_signoff |
| Enfermedades | DIS-NSCLC DIS-PDAC |
| Fuentes | SRC-NCCN-PANCREATIC-2025 |
Datos sobre drogas
| Clase | Taxano (estabilizador de microtubulos; formulación de nanopartículas vinculadas con la albúmina) |
|---|---|
| Mecanismo | Same active moiety as paclitaxel — binds β-tubulin and stabilizes microtubules, blocking mitotic progression. Solvent-free 130-nm nanoparticle formulation: paclitaxel non-covalently bound to human serum albumin. Eliminates Cremophor-EL → no Cremophor hypersensitivity → no corticosteroid / antihistamine premedication required and faster infusion (~30 min). Albumin binding may exploit gp60-mediated endothelial transcytosis and SPARC-mediated tumor accumulation (proposed; clinical relevance debated). Backbone of gem-nab-pac PDAC regimen (MPACT trial). |
| Dosificación típica | Pancreatic 1L gem-nab-pac (MPACT regimen): 125 mg/m² IV over 30-40 min days 1, 8, 15 of 28-day cycle, with gemcitabine 1000 mg/m². Breast metastatic: 260 mg/m² IV over 30 min q21d (mono). NSCLC (with carboplatin AUC 6): 100 mg/m² IV days 1, 8, 15 q21d. TNBC (IMpassion130, with atezolizumab): 100 mg/m² IV days 1, 8, 15 of 28-day cycle. No corticosteroid premedication required (vs Cremophor-paclitaxel). Day-15 dose held for ANC <1.0 / Plt <75 in PDAC schedule. |
| Ucrania registrada | Cierto |
| NSZU reembolsado | Cierto |
| Ucrania verificada por última vez | 2026-04-27 |
Advertencias
- Mielosupresión grave (administración NO recomendada para ANC <1,5)
Notas
No corticosteroid premedication required (vs Cremophor paclitaxel), enabling outpatient infusion + reduced steroid exposure (relevant for diabetic and immunocompromised patients). Day-15 dose typically held for ANC <1.0 or platelets <75 in PDAC gem-nab-pac. PDAC eligibility: PS 0-1, bilirubin <2× ULN. MPACT trial: gem-nab-pac vs gem alone — mOS 8.5 vs 6.7 mo, ORR 23 vs 7%. Compared to FOLFIRINOX: gem-nab-pac better tolerated in older / frail / ECOG 1, FOLFIRINOX superior efficacy in fit ECOG 0. Hepatic dose adjustment: bilirubin 1.26-2.0× ULN reduce to 100 mg/m² (PDAC) or 200 mg/m² (breast); >2-5× ULN reduce to 75 mg/m² (PDAC) or 130 mg/m² (breast).
Utilizado por
Esquema terapéutico
REG-GEM-NAB-PAC- Gemcitabine + nab-paclitaxel (MPACT)REG-PEMBRO-CARBO-NAB-PACLITAXEL-NSCLC-SQ- Pembrolizumab + carboplatin + nab-paclitaxel (squamous NSCLC, first line)